Basic and clinical studies on grepafloxacin in the urological field

T. Takenaka, Toyohiko Watanabe, K. Sakuramoto, T. Hayashi, K. Hata, N. Ono, H. Kumon, H. Ohmori, Y. Katayama, A. Mizuno, M. Kishi, R. Nasu

Research output: Contribution to journalArticle

Abstract

We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4% (8/22) in chronic complicated UTI. Fifteen of 25 (60%) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT · GPT was observed in one case.

Original languageEnglish
Pages (from-to)397-404
Number of pages8
JournalJapanese Journal of Chemotherapy
Volume43
Issue numberSUPPL. 1
Publication statusPublished - 1995

Fingerprint

Ciprofloxacin
Norfloxacin
Prostatitis
Ofloxacin
Cystitis
Drug and Narcotic Control
Quinolones
Eosinophils
Urinary Tract Infections
grepafloxacin
Clinical Studies

Keywords

  • grepafloxacin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Takenaka, T., Watanabe, T., Sakuramoto, K., Hayashi, T., Hata, K., Ono, N., ... Nasu, R. (1995). Basic and clinical studies on grepafloxacin in the urological field. Japanese Journal of Chemotherapy, 43(SUPPL. 1), 397-404.

Basic and clinical studies on grepafloxacin in the urological field. / Takenaka, T.; Watanabe, Toyohiko; Sakuramoto, K.; Hayashi, T.; Hata, K.; Ono, N.; Kumon, H.; Ohmori, H.; Katayama, Y.; Mizuno, A.; Kishi, M.; Nasu, R.

In: Japanese Journal of Chemotherapy, Vol. 43, No. SUPPL. 1, 1995, p. 397-404.

Research output: Contribution to journalArticle

Takenaka, T, Watanabe, T, Sakuramoto, K, Hayashi, T, Hata, K, Ono, N, Kumon, H, Ohmori, H, Katayama, Y, Mizuno, A, Kishi, M & Nasu, R 1995, 'Basic and clinical studies on grepafloxacin in the urological field', Japanese Journal of Chemotherapy, vol. 43, no. SUPPL. 1, pp. 397-404.
Takenaka T, Watanabe T, Sakuramoto K, Hayashi T, Hata K, Ono N et al. Basic and clinical studies on grepafloxacin in the urological field. Japanese Journal of Chemotherapy. 1995;43(SUPPL. 1):397-404.
Takenaka, T. ; Watanabe, Toyohiko ; Sakuramoto, K. ; Hayashi, T. ; Hata, K. ; Ono, N. ; Kumon, H. ; Ohmori, H. ; Katayama, Y. ; Mizuno, A. ; Kishi, M. ; Nasu, R. / Basic and clinical studies on grepafloxacin in the urological field. In: Japanese Journal of Chemotherapy. 1995 ; Vol. 43, No. SUPPL. 1. pp. 397-404.
@article{3d7af7b835de43ad973f3a3f04b874df,
title = "Basic and clinical studies on grepafloxacin in the urological field",
abstract = "We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4{\%} (8/22) in chronic complicated UTI. Fifteen of 25 (60{\%}) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT · GPT was observed in one case.",
keywords = "grepafloxacin",
author = "T. Takenaka and Toyohiko Watanabe and K. Sakuramoto and T. Hayashi and K. Hata and N. Ono and H. Kumon and H. Ohmori and Y. Katayama and A. Mizuno and M. Kishi and R. Nasu",
year = "1995",
language = "English",
volume = "43",
pages = "397--404",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Basic and clinical studies on grepafloxacin in the urological field

AU - Takenaka, T.

AU - Watanabe, Toyohiko

AU - Sakuramoto, K.

AU - Hayashi, T.

AU - Hata, K.

AU - Ono, N.

AU - Kumon, H.

AU - Ohmori, H.

AU - Katayama, Y.

AU - Mizuno, A.

AU - Kishi, M.

AU - Nasu, R.

PY - 1995

Y1 - 1995

N2 - We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4% (8/22) in chronic complicated UTI. Fifteen of 25 (60%) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT · GPT was observed in one case.

AB - We studied the antibacterial activity and clinical usefulness of grepafloxacin (GPFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of GPFX were measured against 210 clinical isolates of 14 species from urinary tract infection and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and norfloxacin (NFLX). In general, the antibacterial activity of GPFX was inferior to CPFX, but equal or superior to those of other control drugs. 2) Clinical efficacy: Although the clinical efficacy in acute uncomplicated cystitis and chronic bacterial prostatitis was good, the overall clinical efficacy rate according to the criteria of the UTI Committee was 36.4% (8/22) in chronic complicated UTI. Fifteen of 25 (60%) strains isolated were eradicated. 3) Side effects: Temporary discomfort of the left side of the body was observed in one case. Mild elevation of eosinophils or GOT · GPT was observed in one case.

KW - grepafloxacin

UR - http://www.scopus.com/inward/record.url?scp=0029096361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029096361&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 397

EP - 404

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -